HOPH.F Stock Overview
A clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Hemogenyx Pharmaceuticals Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0031 |
| 52 Week High | UK£0.04 |
| 52 Week Low | UK£0.0031 |
| Beta | 3.15 |
| 11 Month Change | 0% |
| 3 Month Change | -69.00% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| HOPH.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -3.7% | 0.3% |
| 1Y | n/a | 15.2% | 31.1% |
Return vs Industry: Insufficient data to determine how HOPH.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how HOPH.F performed against the US Market.
Price Volatility
| HOPH.F volatility | |
|---|---|
| HOPH.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HOPH.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine HOPH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 17 | Vladislav Sandler | hemogenyx.com |
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company’s lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, as well as to treat brain cancers and/or certain neurodegenerative diseases; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and cell therapy products for bone marrow/hematopoietic stem cell transplantation.
Hemogenyx Pharmaceuticals Plc Fundamentals Summary
| HOPH.F fundamental statistics | |
|---|---|
| Market cap | US$22.97m |
| Earnings (TTM) | -US$6.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.4x
P/E RatioIs HOPH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HOPH.F income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£5.18m |
| Earnings | -UK£5.18m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0039 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did HOPH.F perform over the long term?
See historical performance and comparison